| Literature DB >> 35299679 |
Kun Chen1, Xiaogang Wang2, Dihang Li1, Weiping Luo1, Chuang Xue1, Yong Kong1.
Abstract
Fibroadenoma of the breast is a common cause of a benign breast lump in premenopausal women. The consensus view is that women with fibroadenomas are not at significantly increased risk of developing breast cancer. The objective of this research was to explore the association of PON1 rs662 and rs705382 with the risk of breast fibroadenoma (BF) and breast cancer (BC) in the females of Guangxi in southern China. The PON1 rs662 and rs705382 single-nucleotide polymorphisms (SNPs) were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 55 BF patients, 80 BC patients, and 98 healthy controls. Significant associations with FB and BC risks were observed for the rs662 SNP. Diagnosis is based on the combination of clinical examination, imaging, and nonsurgical tissue biopsy (the triple test) [21]. In haplotype analyses, the haplotype GA increases the risk and haploid GG decreases the risk in BF and BC. Our research indicated that the PON1 rs662 SNP might be a risk factor for BF and BC. The results of this research indicated that the locus of rs662 in PON1 is relevant to risk of developing BF and BC in the females of Guangxi. Further prospective studies are needed to support our conclusions.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35299679 PMCID: PMC8923756 DOI: 10.1155/2022/3642799
Source DB: PubMed Journal: J Healthc Eng ISSN: 2040-2295 Impact factor: 2.682
Figure 1Electrophoretogram of rs662 locus enzyme-digested product. M lane for marker, lanes 1–12 were PCR enzyme-digested products of 12 specimens, the whole segment length was 99 bp, the lengths of enzyme-digested product segments were 3 bp and 36 bp, 6 for homozygote AA genotype, 1, 2, and 3 for homozygote GG genotype, and 4 and 5 for homozygote AG genotype.
Figure 2Electrophoretogram of rs705382 locus enzyme-digested product. M lane for marker, lanes 1, 2, 3, 4, 5, and 6 were PCR enzyme-digested products of 6 specimens, the whole segment length was 577 bp, the lengths of enzyme-digested product segments were 368 bp and 208 bp, 1 and 2 for homozygote GG genotype, 3 and 4 for heterozygous CG, and 5 and 6 for homozygote CC genotype.
Clinical and epidemiological data for the patient and control groups.
| Parameters | Controls ( | BF ( | BC ( |
|
|---|---|---|---|---|
| Age, | 45.04 6.54 | 34.02 10.81 | 49.67 9.77 | <0.001 |
| BMI, mean SD | 22.57 3.17 | 20.93 3.07 | 22.90 3.24 | 0.01 |
|
| ||||
|
| 3 (3.1%) | 4 (7.3%) | 20 (25%) | <0.001 |
|
| 95 (96.9) | 51 (92.7%) | 60 (75%) | |
|
| ||||
|
| 7 (7.1%) | 8 (14.5%) | 19 (23.8%) | 0.008 |
|
| 91 (92.9) | 47 (85.5%) | 61 (76.35%) | |
|
| ||||
|
| 72 (73.5%) | 49 (89.1%) | 49 (61.3%) | 0.002 |
|
| 23 (23.5%) | 4 (7.3%) | 30 (37.5%) | |
|
| 3 (3.1%) | 2 (3.6%) | 1 (1.3%) |
BMI = body mass index; BF = breast fibroadenoma; BC = breast cancer; SD = standard deviation.
Genotype and allele frequencies of candidate SNPs in patients and control individuals.
| Controls | BF | BC |
| |
|---|---|---|---|---|
| SNPs |
|
|
| |
|
| HWE = 0.989 | <0.001 | ||
|
| 42 (42.9%) | 22 (40.0%) | 30 (37.5%) | |
|
| 11 (11.2%) | 25 (45.5%) | 26 (32.5%) | |
|
| 45 (45.9%) | 8 (14.5%) | 24 (30.0%) | |
|
| 0.003 | |||
|
| 129 (65.8%) | 52 (47.3%) | 84 (52.5%) | |
|
| 67 (34.2%) | 58 (52.7%) | 76 (47.5%) | |
|
| HWE = 0.849 | 0.583 | ||
|
| 21 (21.4%) | 14 (25.5%) | 22 (27.5%) | |
|
| 24 (24.5%) | 11 (20.0%) | 23 (28.8%) | |
|
| 53 (54.1%) | 30 (54.5%) | 35 (43.8%) | |
|
| 0.768 | |||
|
| 95 (48.5%) | 58 (52.7%) | 79 (49.4%) | |
|
| 101 (51.5%) | 52 (47.3%) | 81 (50.6%) |
BF = breast fibroadenoma; BC = breast cancer.
Genotype and allele frequencies of candidate SNPs in patients and control individuals.
| Controls | BF | BC | |||||
|---|---|---|---|---|---|---|---|
| SNPs |
|
| OR (95% CI) | POR |
| OR (95% CI) | POR |
|
| |||||||
|
| 42 (42.9%) | 22 (40.0%) | 1.00ref | 30 (37.5%) | 1.00ref | ||
|
| 11 (11.2%) | 25 (45.5%) | 6.609 (2.077–21.022) | 0.001 | 26 (32.5%) | 3.862 (1.521–9.808) | 0.004 |
|
| 45 (45.9%) | 8 (14.5%) | 0.497 (0.161–1.532) | 0.223 | 24 (30.0%) | 0.569 (0.251–1.290) | 0.177 |
|
| 56 (57.1%) | 33 (60) | 1.586 (0.659–3.818) | 0.304 | 50 (62.5%) | 1.193 (0.599–2.379) | 0.615 |
|
| |||||||
|
| 129 (65.8%) | 52 (47.3%) | 1.00ref | 84 (52.5%) | 1.00ref | ||
|
| 67 (34.2%) | 58 (52.7%) | 2.854 (1.529–5.328) | 0.001 | 76 (47.5%) | 1.878 (1.162–3.034) | 0.01 |
|
| |||||||
|
| 21 (21.4%) | 14 (25.5%) | 1.00ref | 22 (27.5%) | 1.00ref | ||
|
| 24 (24.5%) | 11 (20.0%) | 0.657 (0.187–2.312) | 0.513 | 23 (28.8%) | 0.925 (0.365–2.343) | 0.869 |
|
| 53 (54.1%) | 30 (54.5%) | 1.111 (0.387–3.195) | 0.844 | 35 (43.8%) | 0.579 (0.254–1.320) | 0.194 |
|
| 77 (78.6%) | 41 (74.5%) | 0.949 (0.347–2.592) | 0.919 | 58 (72.5%) | 0.683 (0.317–1.471) | 0.33 |
|
| |||||||
|
| 95 (48.5%) | 58 (52.7%) | 1.00ref | 79 (49.4%) | 1.00ref | ||
|
| 101 (51.5%) | 52 (47.3%) | 0.826 (0.459–1.487) | 0.524 | 81 (50.6%) | 0.963 (0.603–1.538) | 0.875 |
For rs662, codominant model: AG vs GG, GG vs GG, and dominant model: GA + AA. For rs705382, codominant model: CG vs CC, GG vs CC, and dominant model: CG + GG, adjusted for age, smoking, drinking, and BMI.
Haplotype analysis of PON1 rs662 and rs705382 polymorphisms with the risk of BF and BC
| BF vs controls | BC vs controls | ||||||
|---|---|---|---|---|---|---|---|
| Haplotype | Controls (n = 196, %) | BF (n = 110, %) | BC (n = 160, %) | OR (95% CI) | POR | OR( 95% CI) | POR |
| C a | 26.30% | 26.80% | 25.80% | 1.026 [0.605–1.740] | 0.924 | 0.975 [0.606–1.569] | 0.917 |
| C G | 22.20% | 25.90% | 23.60% | 1.229 [0.714–2.117] | 0.457 | 1.082 [0.658–1.779] | 0.755 |
| G a | 7.90% | 24.10% | 21.70% | 3.716 [1.884–7.328] | <0.001 | 3.239 [1.705–6.152] | <0.001 |
| G G | 43.70% | 23.20% | 28.90% | 0.389 [0.230–0.658] | <0.001 | 0.526 [0.338–0.819] | 0.004 |
BF = breast fibroadenoma; BC = breast cancer; CI = confidence interval; OR = odds ratio.